📣 VC round data is live. Check it out!

Susmed Valuation Multiples

Discover revenue and EBITDA valuation multiples for Susmed and similar public comparables like Meditera, Meta Biomed, Xtant Medical, Theraclion and more.

Susmed Overview

About Susmed

Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.


Founded

2015

HQ

Japan

Employees

39

Financials (LTM)

Revenue: $3M
Net Income: ($2M)

EV

$40M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Susmed Financials

Susmed reported last 12-month revenue of $3M.

In the same LTM period, Susmed generated had net loss of ($2M).

Revenue (LTM)


Susmed P&L

In the most recent fiscal year, Susmed reported revenue of $3M and EBITDA of ($2M).

Susmed is unprofitable as of last fiscal year, with gross margin of 90%, EBITDA margin of (59%), and net margin of (60%).

See analyst estimates for Susmed
LTMLast FY202320242025202620272028
Revenue$3M$3M$3M$3M$3M
Gross Profit-$3M$3M$2M$3M
Gross Margin-90%98%97%97%
EBITDA-($2M)($1M)($2M)($2M)
EBITDA Margin-(59%)(46%)(81%)(63%)
EBIT Margin(65%)(60%)(47%)(82%)(65%)
Net Profit($2M)($2M)($1M)($2M)($2M)
Net Margin(65%)(60%)(47%)(81%)(64%)

Financial data powered by Morningstar, Inc.

Susmed Stock Performance

Susmed has current market cap of $65M, and enterprise value of $40M.

Market Cap Evolution


Susmed's stock price is $3.83.

Susmed share price decreased by 11.6% in the last 30 days, and by 0.4% in the last year.

Susmed has an EPS (earnings per share) of $-0.11.

See more trading valuation data for Susmed
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$40M$65M-3.5%-11.6%-36.9%-0.4%$-0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Susmed Valuation Multiples

Susmed trades at 12.7x EV/Revenue multiple, and (21.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Susmed

EV / Revenue (LTM)


Susmed Financial Valuation Multiples

As of June 3, 2026, Susmed has market cap of $65M and EV of $40M.

Susmed has a P/E ratio of (32.1x).

LTMLast FY202320242025202620272028
EV/Revenue12.7x12.7x14.5x15.8x13.7x
EV/EBITDA-(21.8x)(31.6x)(19.5x)(21.8x)
EV/EBIT(19.7x)(21.2x)(30.7x)(19.1x)(21.2x)
EV/Gross Profit-14.1x14.9x16.2x14.1x
P/E(32.1x)(34.5x)(50.5x)(31.4x)(34.5x)
EV/FCF-(14.0x)(80.5x)(18.3x)(14.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Susmed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Susmed Margins & Growth Rates

In the most recent fiscal year, Susmed reported gross margin of 90%, EBITDA margin of (59%), and net margin of (60%).

See estimated margins and future growth rates for Susmed

Susmed Margins

Last FY20242025202720282029
Gross Margin90%97%97%
EBITDA Margin(59%)(81%)(63%)
EBIT Margin(60%)(82%)(65%)
Net Margin(60%)(81%)(64%)
FCF Margin(91%)(86%)(98%)

Susmed Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(8%)15%
Gross Profit Growth(8%)15%
EBITDA Growth62%(10%)
EBIT Growth61%(10%)
Net Profit Growth61%(9%)
FCF Growth339%31%

Data powered by FactSet, Inc. and Morningstar, Inc.

Susmed Operational KPIs

Susmed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Susmed
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$0.1M---
G&A Expenses to Revenue96%97%115%103%
R&D Expenses to Revenue55%48%64%59%
Opex to Revenue151%145%180%162%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Susmed Competitors

Susmed competitors include Meditera, Meta Biomed, Xtant Medical, Theraclion, Osang Healthcare, SMAIO, Spectral AI, Austco Healthcare, Pangaea Oncology and Tobii.

Most Susmed public comparables operate across Healthcare Software, Medical Devices, B2B SaaS, Vertical SaaS, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Meditera0.9x-12.1x-
Meta Biomed1.0x-5.0x-
Xtant Medical0.5x0.6x4.3x7.2x
Theraclion67.2x-(9.5x)-
Osang Healthcare0.8x-9.2x-
SMAIO5.8x5.1x(60.2x)(63.8x)
Spectral AI3.3x3.3x(14.1x)-
Austco Healthcare0.9x0.8x6.6x5.4x

This data is available for Pro users. Sign up to see all Susmed competitors and their valuation data.

Start Free Trial

Susmed VC Funding History

Before going public, Susmed raised $7M in total equity funding, across 2 rounds.


Susmed Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-18Series ABeyond Next Ventures; Dai-ichi Life; M3 Inc.; SBI Investment; Sony Innovation Fund; Tokyo Century$7M--
Feb-17SeedBeyond Next Ventures$900K--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Susmed

When was Susmed founded?Susmed was founded in 2015.
Where is Susmed headquartered?Susmed is headquartered in Japan.
How many employees does Susmed have?As of today, Susmed has over 39 employees.
Is Susmed publicly listed?Yes, Susmed is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Susmed?Susmed trades under 4263 ticker.
When did Susmed go public?Susmed went public in 2021.
Who are competitors of Susmed?Susmed main competitors include Meditera, Meta Biomed, Xtant Medical, Theraclion, Osang Healthcare, SMAIO, Spectral AI, Austco Healthcare, Pangaea Oncology, Tobii.
What is the current market cap of Susmed?Susmed's current market cap is $65M.
What is the current revenue of Susmed?Susmed's last 12 months revenue is $3M.
What is the current EV/Revenue multiple of Susmed?Current revenue multiple of Susmed is 12.7x.
Is Susmed profitable?No, Susmed is not profitable.
What is the current net income of Susmed?Susmed's last 12 months net income is ($2M).
How many companies Susmed has acquired to date?Susmed hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Susmed has invested to date?Susmed hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Susmed

Lists including Susmed

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial